Eduardo Rene Salas Net Worth

The estimated Net Worth of Eduardo Rene Salas is at least $117 millier dollars as of 23 June 2024. Eduardo Salas owns over 1,567 units of Intra-Cellular Therapies Inc stock worth over $117,086 and over the last 3 years Eduardo sold ITCI stock worth over $0.

Eduardo Salas ITCI stock SEC Form 4 insiders trading

Eduardo has made over 1 trades of the Intra-Cellular Therapies Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Eduardo exercised 1,567 units of ITCI stock worth $117,086 on 23 June 2024.

The largest trade Eduardo's ever made was exercising 1,567 units of Intra-Cellular Therapies Inc stock on 23 June 2024 worth over $117,086. On average, Eduardo trades about 313 units every 0 days since 2022. As of 23 June 2024 Eduardo still owns at least 1,567 units of Intra-Cellular Therapies Inc stock.

You can see the complete history of Eduardo Salas stock trades at the bottom of the page.

What's Eduardo Salas's mailing address?

Eduardo's mailing address filed with the SEC is C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK, NY, 10016.

Insiders trading at Intra-Cellular Therapies Inc

Over the last 11 years, insiders at Intra-Cellular Therapies Inc have traded over $77,703,646 worth of Intra-Cellular Therapies Inc stock and bought 3,068,522 units worth $52,322,638 . The most active insiders traders include Rory B Riggs, Joel S Marcus et Christopher D Alafi. On average, Intra-Cellular Therapies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,787,280. The most recent stock trade was executed by Sharon Mates on 29 August 2024, trading 70,000 units of ITCI stock currently worth $891,100.

What does Intra-Cellular Therapies Inc do?

intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.

Complete history of Eduardo Salas stock trades at Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc executives and stock owners

Intra-Cellular Therapies Inc executives and other stock owners filed with the SEC include:

• Sharon Mates,
  Chairman of the Board, President, Chief Executive Officer
• Mark Neumann,
  Executive Vice President, Chief Commercial Officer
• Michael Halstead,
  Executive Vice President, General Counsel and Secretary
• Lawrence Hineline,
  Chief Financial Officer, Senior Vice President - Finance, Treasurer, Assistant Secretary
• Robert Davis,
  Senior Vice President and Chief Scientific Officer
• Kimberly Vanover,
  Senior Vice President, Early Stage Clinical Development and Translational Medicines
• Dr. Sharon Mates,
  Co-Founder, Chairman, CEO & Pres
• Mark Neumann,
  EVP & Chief Commercial Officer
• Michael I. Halstead J.D.,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Suresh K. Durgam M.D.,
  Sr. VP & Chief Medical Officer
• Lawrence J. Hineline CPA, CPA,
  Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
• Robert Van Nostrand,
  Lead Independent Director
• Joel Marcus,
  Independent Director
• Christopher Alafi,
  Independent Director
• Rory Riggs,
  Independent Director
• Richard Lerner,
  Independent Director
• Michael Olchaskey,
  Senior Vice President, Head of Regulatory Affairs
• Suresh Durgam,
  Chief Medical Officer
• John Bardi,
  Senior Vice President - Market Access, Policy and Government Affairs
• Karen Patruno Sheehy Esq.,
  Sr. VP & Chief Compliance Officer
• Juan Fernando Sanchez,
  VP of Corp. Communications & Investor Relations
• Dr. Robert E. Davis Ph.D.,
  Sr. VP & Chief Scientific Officer
• Moshe Alafi,
  10% owner
• Capital Co Llc Alafi,
  10% owner
• Juan F. Sanchez,
  VP, Corp. Communications & IR
• Allen A. Fienberg,
  VP of Business Development
• Lawrence P. Wennogle,
  Vice President, Drug Discovery
• Michael Rawlins,
  Director
• Eduardo Rene Salas,
  
• Sanjeev Narula,
  Executive Vice President & CFO